CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin–TGFβ signaling

Cells of origin in cancer

(2011) Jane E. Visvader   NATURE

Integrin–TGF-β crosstalk in fibrosis, cancer and wound healing

(2010) Coert Margadant et al.   EMBO REPORTS

Proteomic characterization of Her2/neu-overexpressing breast cancer cells

(2010) Hexin Chen et al.   PROTEOMICS

Clinical relevance of the putative stem cell marker p63 in breast cancer

(2009) L. Hanker et al.   BREAST CANCER RESEARCH AND TREATMENT

The Tumor Suppressor p53 Regulates Polarity of Self-Renewing Divisions in Mammary Stem Cells

(2009) Angelo Cicalese et al.   CELL

Tumor-Initiating Cells of HER2-Positive Carcinoma Cell Lines Express the Highest Oncoprotein Levels and Are Sensitive to Trastuzumab

(2009) A. Magnifico et al.   CLINICAL CANCER RESEARCH

The basics of epithelial-mesenchymal transition

(2009) Raghu Kalluri et al.   JOURNAL OF CLINICAL INVESTIGATION

Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers

(2009) Elgene Lim et al.   NATURE MEDICINE

The Mammary Progenitor Marker CD61/ 3 Integrin Identifies Cancer Stem Cells in Mouse Models of Mammary Tumorigenesis

(2008) F. Vaillant et al.   CANCER RESEARCH

The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells

(2008) Sendurai A. Mani et al.   CELL

Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy

(2008) X. Li et al.   JNCI-Journal of the National Cancer Institute

HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion

(2008) H Korkaya et al.   ONCOGENE